Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Update Following General Election

December 16, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.  

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level.  As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

The Company and its partners are strategically well positioned, with Sensyne’s unique NHS partnership model providing a shared financial return back into the NHS.

Lord (Paul) Drayson, CEO of Sensyne Health plc, said:
“Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications
+44 (0) 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com


About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Update Following General Election

December 16, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.  

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level.  As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

The Company and its partners are strategically well positioned, with Sensyne’s unique NHS partnership model providing a shared financial return back into the NHS.

Lord (Paul) Drayson, CEO of Sensyne Health plc, said:
“Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications
+44 (0) 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com


About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Update Following General Election

Update Following General Election

December 16, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.  

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level.  As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

The Company and its partners are strategically well positioned, with Sensyne’s unique NHS partnership model providing a shared financial return back into the NHS.

Lord (Paul) Drayson, CEO of Sensyne Health plc, said:
“Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications
+44 (0) 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com


About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Update Following General Election

Update Following General Election

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.  

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level.  As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

The Company and its partners are strategically well positioned, with Sensyne’s unique NHS partnership model providing a shared financial return back into the NHS.

Lord (Paul) Drayson, CEO of Sensyne Health plc, said:
“Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications
+44 (0) 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com


About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Arrange to meet us
Press release

Update Following General Election

December 16, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.  

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level.  As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

The Company and its partners are strategically well positioned, with Sensyne’s unique NHS partnership model providing a shared financial return back into the NHS.

Lord (Paul) Drayson, CEO of Sensyne Health plc, said:
“Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications
+44 (0) 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com


About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology'. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).